November 11, 2025 — Leads & Copy — Sanara MedTech Inc. (Nasdaq: SMTI) has completed its evaluation of strategic alternatives for its Tissue Health Plus (THP) segment and initiated a strategic realignment, discontinuing THP operations to improve efficiency and reallocate resources to its core surgical business.
The decision, made in late September, was based on a review by Sanara’s management and Board of Directors. Seth Yon, Sanara’s President and CEO, stated that ceasing THP development allows the company to focus on its surgical business, which they believe has greater potential for long-term growth and shareholder value.
Yon highlighted the consistent net revenue growth of Sanara’s surgical business over the past several years, attributing it to the strength of their surgical products, team capabilities, and go-to-market strategy. The strategic realignment aims to allocate capital toward opportunities with the highest expected returns, which will be further discussed during the third-quarter earnings call scheduled for tomorrow morning.
As a result of the realignment, THP operations will be classified as discontinued operations in Sanara’s financial statements, in accordance with U.S. accounting principles. The wind-down process is expected to continue through the end of 2025. The company anticipates a total cash investment in THP ranging from $5.5 million to $6.5 million in the second half of 2025, with no material cash expenses expected after year-end.
Sanara MedTech Inc. develops and commercializes transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. The company develops, markets, and distributes surgical products for use by physicians and clinicians in hospitals, aiming to provide better clinical outcomes at a lower overall cost for patients. Its products are primarily sold in the North American surgical tissue repair markets.
Sanara’s product portfolio includes CellerateRX® Surgical Activated Collagen® Powder, BIASURGE® Advanced Surgical Solution, FORTIFY TRG® Tissue Repair Graft, FORTIFY FLOWABLE® Extracellular Matrix, ACTIGEN® Verified Inductive Bone Matrix, ALLOCYTE® Plus Advanced Viable Bone Matrix, BiFORM® Bioactive Moldable Matrix, and TEXAGEN® Amniotic Membrane Allograft.
The company aims to drive its pipeline from concept to preclinical and clinical development, adhering to quality and regulatory standards, and seeks to expand its offerings for patients in the United States.
Jack Powell or Mike Piccinino, CFA
ICR Healthcare
IR@sanaramedtech.com
Source: Sanara MedTech Inc.
